Evidence map›Paper›PMID 32000764›Full record

ArticleBMC medical ethics2020

Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study.

Marlies Saelaert, Heidi Mertes, Tania Moerenhout, Elfride De Baere, Ignaas Devisch

Abstract readMulticenter Study
In one paragraph

Article in BMC medical ethics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Personal Tools and Psychosocial Resources of Resilient Gender-Based Violence Women.International journal of environmental research and public health · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marlies SaelaertDepartment of Public Health and Primary Care, Philosophy of Medicine and Ethics Research Group, Ghent University, Corneel Heymanslaan 10 - Building 6K3, 9000, Ghent, Belgium. Marlies.Saelaert@ugent.be.ORCID 0000-0002-3607-1578
Heidi MertesDepartment of Philosophy and Moral Sciences, Bioethics Institute Ghent, Ghent University, Ghent, Belgium.
Tania MoerenhoutDepartment of Public Health and Primary Care, Philosophy of Medicine and Ethics Research Group, Ghent University, Corneel Heymanslaan 10 - Building 6K3, 9000, Ghent, Belgium.
Elfride De BaereCenter for Medical Genetics Ghent (CMGG), Ghent University and Ghent University Hospital, Ghent, Belgium.
Ignaas DevischDepartment of Public Health and Primary Care, Philosophy of Medicine and Ethics Research Group, Ghent University, Corneel Heymanslaan 10 - Building 6K3, 9000, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncidental findings (IFs) and secondary findings (SFs), being results that are unrelated to the diagnostic question, are the subject of an important debate in the practice of clinical genomic medicine. Arguments for reporting these results or not doing so typically relate to the principles of autonomy, non-maleficence and beneficence. However, these principles frequently conflict and are insufficient by themselves to come to a conclusion. This study investigates empirically how ethical principles are considered when actually reporting IFs or SFs and how value conflicts are weighed.

methodsA qualitative focus group study has been undertaken, including a multidisciplinary group of professionals from Belgian centres for medical genetics. The data were analysed thematically.

resultsAll eight Belgian centres participated in this study. Ethical values were frequently referred to for disclosure policies on IFs and SFs. Participants invoked respect for patient autonomy to support the disclosure of IFs and opt-out options for IFs and SFs, non-maleficence for the professional delineation of reportable IFs and opt-out options for IFs and SFs and (the particular scope of) beneficence for the mandatory reporting of actionable IFs, the delineation of reportable IFs and a current decline of actively pursued SFs. Professional assumptions about patients' genetic literacy were an important factor in the weighing of values.

conclusionsIn line with the traditional bioethical discourse, the mandatory reporting of actionable IFs might be interpreted as a "technological, soft paternalism". Restricting patients' choices might be acceptable, but then its motives should be valid and its beneficent outcomes highly plausible. Hence, the presuppositions of technological, soft paternalism - patients' inability to make informed decisions, normative rationality, the efficacy of beneficent outcomes and the delineated spectrum of beneficence - should be approached critically. Moreover, distributive justice should be considered an important value in the delineation of the current scope of the ethical debate on IFs and SFs. This study of guiding values may stimulate the debate on the ethical grounds for a solid policy on IFs and SFs internationally.

Indexed as

Attitude of Health PersonnelBelgiumDisclosureFocus GroupsGenomicsHumansIncidental FindingsInterviews as TopicPersonal AutonomyQualitative ResearchClinical genomic testingDistributive justiceIncidental findingsPatient autonomyProfessional beneficenceQualitative researchSecondary findingsSoft paternalism

Identifiers

PMID32000764
PMCPMC6990492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.